We could not find any results for:
Make sure your spelling is correct or try broadening your search.
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for... XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States. Show more
AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotechΒ (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for...
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand itβs campus headquarters with the construction of a new, state-of-the-art research and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.72 | 10.8597285068 | 6.63 | 7.23 | 6.36 | 41773 | 6.71827169 | CS |
4 | 0.14 | 1.94174757282 | 7.21 | 8.32 | 6.36 | 50210 | 7.20625778 | CS |
12 | 1.65 | 28.9473684211 | 5.7 | 8.32 | 5.62 | 45269 | 7.13838274 | CS |
26 | -1.11 | -13.1205673759 | 8.46 | 8.6352 | 4.24 | 87047 | 6.17579329 | CS |
52 | 3.5 | 90.9090909091 | 3.85 | 9.96 | 3.6 | 70576 | 6.57350147 | CS |
156 | -5.77 | -43.9786585366 | 13.12 | 13.12 | 3 | 63439 | 6.31660868 | CS |
260 | -4.36 | -37.2331340734 | 11.71 | 33.2 | 3 | 130289 | 14.45095661 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions